PCPatrick Cras

Patrick Cras

*This is an algorithmically generated author record based on publicly available information.

Patrick Cras has a total of 327 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Etiological Spectrum of Non-Compressive Myelopathies in Uganda

    by Abdu Kisekka Musubire, Kristoffer E. Leon, Eoin P. Flanagan, Prashanth S. Ramachandran, Chloe Gerungan, Kelsey C. Zorn, Annie Wapniarski, David B. Meya, Paul M. Mubiri, Twaha Kisozi, et al.

    Background: Non-compressive myelopathy can lead to severe disability and death. The diagnosis is often complex and resource-intensive, with regional variation in causes. Data on the epidemiology and etiology of non-compressive myelopathy in Africa remains limited. Methods: Using consecutive sampling, we performed a cross-sectional analysis within an established cohort of adult patients hospitalized in medical wards, all of whom exhibited clinical signs and symptoms consistent with non-compressive myelopathy at two tertiary hospitals in Kampala, Uganda. Consent was obtained from admitted patients over the age of eighteen who presented with clinical signs and symptoms of non-compressive myelopathy. Participants underwent spine magnetic resonance imaging (MRI) to rule out extradural spinal cord lesions. Serum and cerebrospinal fluid (CSF) aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibody testing and CSF metagenomic next-generation sequencing (mNGS) were performed. Tissue biopsies and serum vitamin B12 levels were carried out at the discretion of the clinician. Descriptive statistics were used to summarize the diagnostic results and participant characteristics. Findings: Among 420 participants screened, 144 were enrolled and included in this analysis. Seventy-nine (55%) were male, the median age was 33 years (IQR 25-44), and 38 (26%) were people living with HIV. Intradural abnormalities were identified on spinal MRI in 79 (55%) participants. An etiologic diagnosis was established in 45 (32%) participants, including neuromyelitis optica spectrum disorder (NMOSD, n=10), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD, n=7), Schistosoma mansoni (n=8), cytomegalovirus (n=1), varicella zoster virus (n=1), vitamin B12 myelopathy (n=8), infiltrating spinal cord tumor (n=8), and arteriovenous malformation (n=2). Interpretation: This study identified a wide range of etiologies for non-compressive myelopathy in Uganda, including autoimmune myelopathies (NMOSD and MOGAD) and infectious myelopathies. These findings highlight the importance of expanding access to both autoimmune and infectious diagnostic testing in Africa.

  • Open Access

    A repeat expansion in GOLGA8A is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions

    by Wouter De Coster, Marleen Van Den Broeck, Matt Baker, Nikhil B. Ghayal, Sarah Wynants, Anthony Batzler, Cyril Pottier, Sara Alidadiani, Fahri Küçükali, Gregory D. Jenkins, et al.

    Atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions (aFTLD-U) is neuropathologically characterized by aggregation of the FET family of proteins and clinically manifests as sporadic young-onset frontotemporal dementia. Here we describe a major risk locus on chr15q14 identified through a genome-wide association study in 59 pathologically confirmed aFTLD-U cases and 3,153 controls (lead single nucleotide polymorphism rs549846383, P = 5.85 × 10 −21 , odds ratio 26.7). When combined with data from 28 additional aFTLD-U cases, 3,712 controls and 3,215 individuals with other neurodegenerative diseases and by leveraging in-house and public long-read genome sequencing data from 1,715 individuals, we identified a tandem repeat expansion on the associated haplotypes in an intron of GOLGA8A . We found variation in repeat length, motif length, and motif sequence, with long CT-dimer expansions strongly associated with aFTLD-U. Although the functional consequence of this repeat remains unknown, its presence in nearly 60% of aFTLD-U cases points to a fundamental role in disease pathogenesis.


  • Nervous system tumors as subject of multidisciplinary oncological consult

    by Laurens Dobbels, Bernard Hanseeuw, Ludo Vanopdenbosch, Anne Sieben, Patrick Cras

  • Open Access

    The 2022 European postgraduate (residency) programme in neurology in a historical and international perspective

    by Claudio L. A. Bassetti, Riccardo Soffietti, David B. Vodušek, Benedikt Schoser, Jan B. M. Kuks, Martin Rakusa, Patrick Cras, Paul A. J. M. Boon

    Background and purpose: Neurology residency programmes, which were first established at the beginning of the 20th century, have become mandatory all over Europe in the last 40–50 years. The first European Training Requirements in Neurology (ETRN) were published in 2005 and first updated in 2016. This paper reports the most recent revisions of the ETRN.Methods: Members of the EAN board performed an in depth revision of the ETNR 2016‐version, which was reviewed by members of the European Board and Section of Neurology of the UEMS, the Education and Scientific Panels, the Resident and Research Fellow Section and the Board of the EAN, as well as the presidents of the 47 European National Societies.Results: The new (2022) ETRN suggest a 5‐year training subdivided in three phases: a first phase (2 years) of general neurology training, a second phase (2 years) of training in neurophysiology/neurological subspecialties and a third phase (1 year) to expand clinical training (e.g., in other neurodisciplines) or for research (path for clinical neuroscientist). The necessary theoretical and clinical competences as well as learning objectives in diagnostic tests have been updated, are newly organized in four levels and include 19 neurological subspecialties. Finally, the new ETRN require, in addition to a programme director, a team of clinician‐educators who regularly review the resident's progress.The 2022 update of the ETRN reflects emerging requirements for the practice of neurology and contributes to the international standardization of training necessary for the increasing needs of residents and specialists across Europe.


  • Open Access

    Is vestibular function related to human hippocampal volume?

    by Joyce Bosmans, Hanne Gommeren, Peter zu Eulenburg, Annick Gilles, Griet Mertens, Angelique Van Ombergen, Patrick Cras, Sebastiaan Engelborghs, Vincent Van Rompaey

    INTRODUCTION Recent studies implicate the effect of vestibular loss on cognitive decline, including hippocampal volume loss. As hippocampal atrophy is an important biomarker of Alzheimer’s disease, exploring vestibular dysfunction as a risk factor for dementia and its role in hippocampal atrophy is of interest. METHODS Hippocampal and whole-brain MRI volumes were compared in adults aged between 55 and 83 years: (1) to substantiate previous literature, bilateral vestibulopathy (BV) was compared to healthy controls, (2) to correct for a potential confounding effect of concomitant hearing loss, BV was compared to healthy controls matched on age, sex, and hearing status, (3) to additionally evaluate the isolated effect of hearing loss on brain structure, sensorineural hearing loss (SNHL) was compared to healthy controls. Furthermore, to delineate otolith influence on hippocampal volume in preserved vestibular function (healthy controls and SNHL combined), saccular function was investigated. RESULTS Whole-brain and targeted hippocampal approaches using volumetric and surface-based measures yielded no significant differences in either of three comparisons: (1) BV versus controls, (2) BV versus matched controls, and (3) SNHL versus controls. Binary support vector machines were unable to classify inner ear health status above chance level. Otolith parameters were significantly associated with hippocampal volume in preserved vestibular function. CONCLUSION No significant differences in whole-brain or hippocampal volume were found when comparing BV with healthy controls, nor did concomitant SNHL confound this relationship. Otolith function may be associated with hippocampal volume rather than lateral semicircular canal integrity. Future BV studies should generally incorporate otolith function testing. Key points Recent research suggests an association between vestibular function and cognition. Hippocampal atrophy is an important biomarker of Alzheimer’s disease. Bilateral vestibular loss did not modulate hippocampal or whole-brain volume. Otolith function may influence hippocampal volume. Future vestibular research should incorporate otolith function testing.

  • Open Access

    Apathy in Parkinson’s Disease: Defining the Park Apathy Subtype

    by Ségolène De Waele, Patrick Cras, David Crosiers

    Apathy is a neurobehavioural symptom affecting Parkinson’s disease patients of all disease stages. Apathy seems to be associated with a specific underlying non-motor disease subtype and reflects dysfunction of separate neural networks with distinct neurotransmitter systems. Due to the complicated neuropsychiatric aetiology of apathy, clinical assessment of this invalidating non-motor symptom remains challenging. We aim to summarize the current findings on apathy in Parkinson’s disease and highlight knowledge gaps. We will discuss the prevalence rates across the different disease stages and suggest screening tools for clinically relevant apathetic symptoms. We will approach the fundamental knowledge on the neural networks implicated in apathy in a practical manner and formulate recommendations on patient-tailored treatment. We will discuss the Park apathy phenotype in detail, shedding light on different clinical manifestations and implications for prognosis. With this review, we strive to distil the vast available theoretical knowledge into a clinical and patient-oriented perspective.


  • Open Access

    Neuromyelitis Optica Spectrum Disorders in Africa

    by Abdu Kisekka Musubire, Judith Derdelinckx, Tatjana Reynders, David B. Meya, Paul R. Bohjanen, Patrick Cras, Barbara Willekens

    Background and Objectives Neuromyelitis optica (NMO) is a CNS inflammatory disease that predominantly affects the optic nerves and the spinal cord. It is more frequent in Asian and African populations than in European ones. Data on epidemiology, clinical presentation, additional investigations, and treatment in the African continent are scarce. We aim to (1) collect and analyze published data on neuromyelitis optica spectrum disorder (NMOSD), (2) indicate challenges in the diagnosis and management, and (3) discuss opportunities for future research, education, and policy making, specifically on the African continent. Methods A systematic review was performed in January 2021 with the search terms “Neuromyelitis optica and Africa,” “Devic Disease and Africa,” and “NMOSD and Africa.” We included all study types except case reports, correspondence, or conference abstracts on NMO or NMOSD. Extracted data included study design, country, study period, demographic and clinical characteristics, results of paraclinical investigations, and outcome. Data analysis was performed with descriptive statistics. Results We retrieved a total of 79 records, of which 19 were included. Ten of 54 African countries reported a total of 410 cases. Almost half of them were from North African countries. The mean age at diagnosis was 33 years (range 7–88 years), and 75% were female. Transverse myelitis followed by optic neuritis were the most frequent symptoms at the time of presentation. One hundred nineteen patients experienced at least 1 previous relapse, and 106 had a relapsing course after diagnosis. Relapses were treated with IV methylprednisolone. Azathioprine and steroids were used most often as maintenance treatments. Outcomes were rarely described. Discussion The majority of studies on NMOSD from the African continent are retrospective, and most countries do not report any data. Our systemic review shows that data derived from patients living in Africa correspond well to what has been previously published in meta-analyses on patients of African ancestry with NMOSD who live outside of Africa, except for a younger age at onset and a lower proportion of females. We advocate for systematic data collection to adequately capture and monitor the burden of NMOSD, for expansion of research efforts and facilities to perform fundamental and clinical research, and for improved access to health care including diagnostics, treatments, and rehabilitation services for people affected by NMOSD in the African continent.


  • Open Access

    HLA Class II Genotype Does Not Affect the Myelin Responsiveness of Multiple Sclerosis Patients

    by Judith Derdelinckx, Irene Nkansah, Naomi Ooms, Laura Van Bruggen, Marie-Paule Emonds, Liesbeth Daniëls, Tatjana Reynders, Barbara Willekens, Patrick Cras, Zwi N. Berneman, et al.

    Background: When aiming to restore myelin tolerance using antigen-specific treatment approaches in MS, the wide variety of myelin-derived antigens towards which immune responses are targeted in multiple sclerosis (MS) patients needs to be taken into account. Uncertainty remains as to whether the myelin reactivity pattern of a specific MS patient can be predicted based upon the human leukocyte antigen (HLA) class II haplotype of the patient. Methods: In this study, we analyzed the reactivity towards myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP) and proteolipid protein (PLP) peptides using direct interferon (IFN)-γ enzyme-linked immune absorbent spot (ELISPOT). Next, the HLA class II haplotype profile was determined by next-generation sequencing. In doing so, we aimed to evaluate the possible association between the precursor frequency of myelin-reactive T cells and the HLA haplotype. Results: Reactivity towards any of the analyzed peptides could be demonstrated in 65.0% (13/20) of MS patients and in 60.0% (6/10) of healthy controls. At least one of the MS risk alleles HLA-DRB1*15:01, HLA-DQA1*01:02 and HLA-DQB1*06:02 was found in 70.0% (14/20) of patients and in 20.0% (2/10) of healthy controls. No difference in the presence of a myelin-specific response, nor in the frequency of myelin peptide-reactive precursor cells could be detected among carriers and non-carriers of these risk alleles. Conclusion: No association between HLA haplotype and myelin reactivity profile was present in our study population. This complicates the development of antigen-specific treatment approaches and implies the need for multi-epitope targeting in an HLA-unrestricted manner to fully address the wide variation in myelin responses and HLA profiles in a heterogeneous group of MS patients.


  • Open Access

    Predictors of 30-day and 90-day mortality among hemorrhagic and ischemic stroke patients in urban Uganda: a prospective hospital-based cohort study

    by Gertrude Namale, Onesmus Kamacooko, Anthony Makhoba, Timothy Mugabi, Maria Ndagire, Proscovia Ssanyu, John Bosco M. Ddamulira, Laetitia Yperzeele, Patrick Cras, Edward Ddumba, et al.

    Background: We report here on a prospective hospital-based cohort study that investigates predictors of 30-day and 90-day mortality and functional disability among Ugandan stroke patients. Methods: Between December 2016 and March 2019, we enrolled consecutive hemorrhagic stroke and ischemic stroke patients at St Francis Hospital Nsambya, Kampala, Uganda. The primary outcome measure was mortality at 30 and 90 days. The modified Ranking Scale wasused to assess the level of disability and mortality after stroke. Stroke severity at admission was assessed using the National Institute of Health Stroke Scale (NIHSS) and Glasgow Coma Scale (GCS). Examination included clinical neurological evaluation, laboratory tests and brain computed tomography (CT) scan. Kaplan-Meier curves and multivariate Cox proportional hazard model were used for unadjusted and adjusted analysis to predict mortality. Results: We enrolled 141 patients; 48 (34%) were male, mean age was 63.2 (+ 15.4) years old; 90 (64%) had ischemic and 51 (36%) had hemorrhagic stroke; 81 (57%) were elderly (≥ 60 years) patients. Overall mortality was 44 (31%); 31 (23%) patients died within the first 30 days post-stroke and, an additional 13 (14%) died within 90 days post-stroke. Mortality for hemorrhagic stroke was 19 (37.3%) and 25 (27.8%) for ischemic stroke. After adjusting for age and sex, a GCS score below < 9 (adjusted hazard ratio [aHR] =3.49, 95% CI: 1.39–8.75) was a significant predictor of 30-day mortality. GCS score < 9 (aHR =4.34 (95% CI: 1.85–10.2), stroke severity (NIHSS ≥21) (aHR = 2.63, 95% CI: (1.68–10.5) and haemorrhagic stroke type (aHR = 2.30, 95% CI: 1.13–4.66) were significant predictors of 90-day mortality. Shorter hospital stay of 7–13 days (aHR = 0.31, 95% CI: 0.11–0.93) and being married (aHR = 0.22 (95% CI: 0.06–0.84) had protective effects for 30 and 90-day mortality respectively. Conclusion: Mortality is high in the acute and sub-acute phase of stroke. Low levels of consciousness at admission, stroke severity, and hemorrhagic stroke were associated with increased higher mortality in this cohort of Ugandan stroke patients. Being married provided a protective effect for 90-day mortality. Given the high mortality during the acute phase, critically ill stroke patients would benefit from early interventions established as the post-stroke- standard of care in the country.


  • Open Access

    Does Motor Cortex Engagement During Movement Preparation Differentially Inhibit Nociceptive Processing in Patients with Chronic Whiplash Associated Disorders, Chronic Fatigue Syndrome and Healthy Controls? An Experimental Study

    by Lisa Goudman, André Mouraux, Liesbeth Daenen, Jo Nijs, Patrick Cras, Nathalie Roussel, Maarten Moens, Dorine Lenoir, Iris Coppieters, Eva Huysmans, et al.

    Background: Patients with chronic fatigue syndrome (CFS) and chronic whiplash associated disorders (cWAD) present a reduced ability to activate central descending nociceptive inhibition after exercise, compared to measurements before exercise. It was hypothesised that a dysfunctional motor-induced inhibition of nociception partly explains this dysfunctional exercise-induced hypoalgesia. This study investigates if engagement of the motor system during movement preparation inhibits nociception-evoked brain responses in these patients as compared to healthy controls (HC). Methods: The experiment used laser-evoked potentials (LEPs) during three conditions (no task, mental task, movement preparation) while recording brain activity with a 32-channel electroencephalogram in 21 patients with cWAD, 20 patients with CFS and 18 HC. Two-factor mixed design Analysis of variance were used to evaluate differences in LEP amplitudes and latencies. Results: No differences in N1, N2, N2P2, and P2 LEP amplitudes were found between the HC, CFS, and cWAD groups. After nociceptive stimulation, N1, N2 (only at hand location), N2P2, and P2 LEP amplitudes significantly decreased during movement preparation compared to no task (within group differences). Conclusion: Movement preparation induces a similar attenuation of LEPs in patients with CFS, patients with cWAD and HC. These findings do not support reduced motor-induced nociceptive inhibition in these patients.